Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

Kuva Labs Inc. has commenced a tender offer to acquire Lisata Therapeutics for $4.00 per share in cash plus contingent value rights worth up to $3.00 per share based on achievement of clinical milestones. The transaction values Lisata at a premium to historical market prices and is expected to close in Q3 2026. Lisata's Board unanimously recommends stockholders tender their shares.

06/10/2026, 8:00 AM • Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA)

Law firm Brodsky & Smith has initiated investigations into four merger transactions, examining whether the boards of KalVista Pharmaceuticals, Thermon Group Holdings, Sila Realty Trust, and Lisata Therapeutics breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The deals range in value from approximately $1.9 billion to $2.4 billion.

05/14/2026, 1:49 PM • GlobeNewswire

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—TALK, LSTA, NSA, and KALV

Monteverde & Associates PC is investigating four merger transactions: Talkspace's sale to Universal Health Services at $5.25/share, Lisata Therapeutics' sale to Kuva Labs at $4.00/share plus contingent value rights, National Storage Affiliates Trust's sale to Public Storage at 0.14 shares per unit, and KalVista Pharmaceuticals' sale to Chiesi Group at $27.00/share. The firm is seeking shareholders to determine if the proposed deal terms are fair.

05/12/2026, 11:00 AM • GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - SKYT)

Law firm Brodsky & Smith announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Esperion Therapeutics (ARCHIMED acquisition at $3.16/share), Sila Realty Trust (Blue Owl Capital acquisition at $30.38/share), Lisata Therapeutics (Kuva Labs acquisition at $4.00/share plus CVRs), and SkyWater Technology (IonQ acquisition at $35.00/share).

05/05/2026, 2:56 PM • GlobeNewswire

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating Sila Realty Trust's $30.38 per share sale to Blue Owl Real Estate Capital affiliates and Lisata Therapeutics' $4.00 per share sale to Kuva Labs. The firm is examining potential securities law violations and breaches of fiduciary duties, seeking to determine if shareholders are receiving fair consideration and if insider benefits are being prioritized over ordinary shareholder interests.

05/04/2026, 2:48 PM • GlobeNewswire

URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LSTA, IBCP, HCBN, and SILA

Class action law firm Monteverde & Associates PC announced investigations into several merger and acquisition transactions, including Lisata Therapeutics' sale to Smithfield Foods, Independent Bank Corporation's merger with HCB Financial Corp, and Sila Realty Trust's sale to Sunshine Ultimate Parent LLC. The firm is seeking shareholders who may have concerns about these proposed deals.

05/04/2026, 1:45 PM • GlobeNewswire

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Lisata Therapeutics has agreed to be acquired by privately-held Kuva Labs for $5.00 per share in cash plus a contingent value right of up to $1.00 per share if FDA approval is filed for certepetide within 7 years. The transaction is expected to close in Q2 2026, and Lisata's board unanimously approved the deal. Following completion, Lisata will be delisted from Nasdaq and cease to be a public reporting company.

03/06/2026, 6:15 PM • Benzinga

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Lisata Therapeutics has agreed to be acquired by privately-held Kuva Labs Inc. for $5.00 per share in cash at closing, plus one contingent value right worth up to $1.00 per share if certepetide receives FDA approval within seven years. The transaction, unanimously approved by Lisata's board, is expected to close in Q2 2026 and will result in Lisata being delisted from Nasdaq.

03/06/2026, 6:15 PM • GlobeNewswire

Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential federal securities law violations and breaches of fiduciary duties related to their merger transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.

02/02/2026, 5:52 PM • GlobeNewswire

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA

Monteverde & Associates PC, a class action law firm, is investigating four merger transactions: Penumbra's sale to Boston Scientific, RAPT Therapeutics' sale to GSK, Nathan's Famous' sale to Smithfield Foods, and Lisata Therapeutics' sale to Smithfield Foods. The firm is seeking shareholders who may have concerns about these deals.

01/28/2026, 2:23 PM • Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc. (Nasdaq - VTYX)

Law firm Brodsky & Smith announced investigations into four merger agreements, examining whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Nathan's Famous (acquired by Smithfield Foods for $102/share), Lisata Therapeutics (acquired by Kuva Labs for $4/share plus CVRs), Sun Country Airlines (acquired by Allegiant for $18.89/share equivalent), and Ventyx Biosciences (acquired for $14/share in cash).

01/21/2026, 11:00 AM • GlobeNewswire

Why Is Lisata Therapeutics Stock Gaining Today?

Lisata Therapeutics (NASDAQ: LSTA) shares surged 85.65% after agreeing to be acquired by Kuva Labs for $4.00 per share in cash, representing an 85% premium to recent closing prices. The deal includes two contingent value rights (CVRs) worth up to $2 per share tied to future milestones, bringing the total implied premium to approximately 180%. Both boards unanimously approved the binding term sheet, with a definitive agreement expected by February 27, 2026.

01/21/2026, 10:31 AM • Benzinga

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

Lisata Therapeutics and WARPNINE completed patient enrollment in a Phase 1b/2a trial evaluating certepetide for locally advanced pancreatic cancer, reporting promising preliminary data with a 60% overall response rate and 100% disease control rate.

07/17/2025, 8:00 AM • GlobeNewswire